Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | C3AR1 | Q16581 | 2/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14917141 | 1.00 | P2RX7 (0.38) | P2RX7CNR1GRM4C3AR1FPR2 | |
| SCHEMBL14916629 | 0.84 | GRM4 (0.46) | CNR1GRM4MEN1KMT2AKDM4E | |
| SCHEMBL14916628 | 0.84 | GRM4 (0.46) | CNR1GRM4MEN1KMT2AKDM4E | |
| SCHEMBL14917222 | 0.82 | GRM4 (0.45) | GRM4MEN1KMT2APOLBKDM4E | |
| SCHEMBL10064950 | 0.82 | GRM4 (0.45) | GRM4MEN1KMT2APOLBKDM4E | |
| SCHEMBL10065055 | 0.77 | GSK3B (0.45) | GRM4MEN1KMT2APOLBKDM4E | |
| SCHEMBL14917388 | 0.77 | GSK3B (0.45) | GRM4MEN1KMT2APOLBKDM4E | |
| SCHEMBL14916973 | 0.77 | MAPT (0.45) | MEN1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL10065512 | 0.77 | MAPT (0.45) | MEN1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL14916838 | 0.74 | CTSS (0.36) | CNR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116445-A1 | TRIAZOLIUM CARBENE CATALYSTS AND PROCESSES FOR ASYMMETRIC CARBON-CARBON BOND FORMATION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116445-A1 | TRIAZOLIUM CARBENE CATALYSTS AND PROCESSES FOR ASYMMETRIC CARBON-CARBON BOND FORMATION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116445-A1 | TRIAZOLIUM CARBENE CATALYSTS AND PROCESSES FOR ASYMMETRIC CARBON-CARBON BOND FORMATION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116445-A1 | TRIAZOLIUM CARBENE CATALYSTS AND PROCESSES FOR ASYMMETRIC CARBON-CARBON BOND FORMATION | TIMCC, CYCS, CTRC | P2RX7 4776/4885CNR1 1660/4885GRM4 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.